Vitiligo
Conditions
Brief summary
Patients of non-segmental vitiligo, fulfilling the inclusion criteria will be selected from the OPD, dermatology department. It's an interventional study where Group A patient will be given NBUVB and Tab Apremilast 30 mg twice a day and Group B will receive NBUVB alone.
Detailed description
Patients of non-segmental vitiligo, fulfilling the inclusion criteria will be selected from the OPD, dermatology department Dow university hospital. Informed consent will be obtained from all the patients. Demographic details of patients including age, gender, education, occupation and marital status will be obtained. Further each patient will be asked about duration of vitiligo and any systemic medications used by the patients in the last 6 months will be recorded. Body Surface Area will be calculated and patients with > 5% of BSA will be included in the study. Subjects will be randomly divided by lottery method into two groups. Group A patients will be given NBUVB and Tab Apremilast 30 mg twice a day, and Group B patients will receive NBUVB alone. Hematological baseline including CBC and LFTs will be advised to patients in Group A. Vitiligo Area Severity Index (VASI) will be used to initially assess the patient at the baseline and later on to assess the regimentation in each of the patients of vitiligo on next 4 follow-ups. Each follow-up will be after every 8 weeks for a total of 32 weeks. CBC and LFTs will be repeated in Group A after 4 weeks of starting tab Apremilast 30 mg BD and then after 3 months. Any side effects seen during the study period will be recorded and managed accordingly DLQI Dermatological Life Quality Index (DLQI) questionnaire will be conducted with 30 vitiligo patients at the baseline and at the end of therapy. All results will be collected and filled in proforma by the researcher. The results will be assessed statistically at the end of the follow-up period.
Interventions
COMBINATION_PRODUCTApremilast with NB-UVB
Tab Apremilast 30 mg twice a day with NBUVB twice per week for 8 months
DEVICENB-UVB
NBUVB only will be given twice per week for 8 months
Sponsors
Dow University of Health Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients age 18 years and above * Patients of both genders (male and female) * Diagnosed patients of non-segmental vitiligo involving \> 5% of BSA
Exclusion criteria
* Pregnant and lactating women * Concomitant active infection like tuberculosis * Personal history of cutaneous malignancy * Use of apremilast in the past 4 weeks * Use of phototherapy within 4 weeks before randomization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To determine the frequency of patients halted their progression and extent of repigmentation | 32 weeks | Halt in progression and extent of repigmentation from baseline to week 32 in both groups will be calculated by Scale named Vitiligo Area and Severity Index(VASI) done at the baseline and then at week 8, week 16, week 24 and 32. Score of the scale ranges from 0 -100 . Fall in the score will show the improvement. |
| To determine the frequency of patients showing decrease in the percentage of depigmented areas | 32 weeks | This will be performed by calculating Body surface area (BSA ) at the baseline and at week 32 . The patient's palmar surface including their fingers = 1% BSA Scale grading is as follows, mild (less than 3%) moderate (3-10%) severe (greater than 10%) Fall in the percentage of depigmented area is taken as improvement . |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DLQI Score and Safety | 32 weeks | Dermatology Life Quality Index (DLQI) score at week 32 compared to baseline Scale ranges from 0 to 30 0 - 1 no effect at all, 2 - 5 small effect, 6 -10 moderate effect , 11 - 20 very large effect, 21 - 30 extremely large effect on the life of patient. Decrease in the score will be a marker of improvement |
Other
| Measure | Time frame | Description |
|---|---|---|
| To determine the tolerability and safety of intervention | 32 weeks | Documentation of Adverse Events during therapy |
Countries
Pakistan
Outcome results
None listed